Cardiovascular disease in the developing world and its cost-effective management

被引：284
作者：
Gaziano, TA
机构：
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Cardiol, Boston, MA 02120 USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Social Med, Boston, MA 02120 USA
来源：
CIRCULATION | 2005年 / 112卷 / 23期
关键词：
cost-benefit analysis; epidemiology; heart failure; myocardial infarction; prevention;
D O I：
10.1161/CIRCULATIONAHA.105.591792
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：3547 / 3553
页数：7
相关论文
共 23 条
[1]  
*AM HEART ASS, 2003, HEART DIS STROK STAT
[2]  
[Anonymous], CARDIOVASCULAR DIS D
[3]  
[Anonymous], 2002, World Development Indicators
[4]  
[Anonymous], 2001, MACROECONOMICS HLTH
[5]  
[Anonymous], 2003, WORLD HLTH REPORT 20
[6]  
*DCPP SECR, 2004, DIS CONTR PRIOR PROJ
[7]  
GAZIANO T, IN PRESS CARDIOVASCU
[8]   COST-EFFECTIVENESS OF HMG-COA REDUCTASE INHIBITION FOR PRIMARY AND SECONDARY PREVENTION OF CORONARY HEART-DISEASE [J].
GOLDMAN, L ;
WEINSTEIN, MC ;
GOLDMAN, PA ;
WILLIAMS, LW .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1991, 265 (09) :1145-1151
[9]   Medical care expenditures for hypertension, its complications, and its comorbidities [J].
Hodgson, TA ;
Cai, LM .
MEDICAL CARE, 2001, 39 (06) :599-615
[10]  
Leeder SR., 2004, RACE TIME CHALLENGE
123